What Is Triamcinolone Acetonide Ointment Used For?

What is Triamcinolone Foam and how is it used?

Triamcinolone Foam is a prescription medicine used to treat the symptoms of topical inflammatory dermatoses, oral inflammatory or ulcerative lesions. Triamcinolone Foam may be used alone or with other medications.

Triamcinolone Cream belongs to a class of drugs chosen Corticosteroids, Topical.

What are the possible side effects of Triamcinolone Cream?

Triamcinolone Cream may crusade serious side furnishings including:

worsening of your skin condition,
redness, warmth, swelling, oozing, or severe irritation of any treated skin,
blurred vision,
tunnel vision,
eye pain,
seeing halos effectually lights,
increased thirst,
increased urination,
dry mouth,
fruity breath smell,
weight gain (in your confront, upper back and torso),
slow wound healing,
thinning or discolored skin,
increased body pilus,
muscle weakness,
nausea,
diarrhea,
tiredness,
mood changes,
menstrual changes, and
sexual changes

Get medical assist right abroad, if yous have any of the symptoms listed higher up.

The most common side effects of Triamcinolone Cream include:

burning, itching, dryness or other irritation of the treated pare,
redness or crusting around your pilus follicles,
redness or itching around your mouth,
allergic skin reaction,
stretch marks,
acne,
increased torso hair growth,
thinning skin,
skin discoloration, and
white or "pruned" appearance of the pare

Tell the doctor if you accept any side result that bothers you or that does not become away.

These are not all the possible side furnishings of Triamcinolone Cream. For more data, ask your medico or pharmacist.

Call your physician for medical advice about side effects. You lot may report side effects to FDA at ane-800-FDA-1088.

Clarification

The topical corticosteroids constitute a class of primarily constructed steroids used as anti-inflammatory and antipruritic agents. The steroids in this grade include Triamcinolone Acetonide (triamcinolone acetonide foam) . Triamcinolone Acetonide (triamcinolone acetonide foam) is designated chemically as 9-Fluoro-11β,16α,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. With the molecular formula of C₂₄H₃₁FO₆ and a molecular weight of 434.51. The structural formula is:

Triamcinolone Acetonide structural formula illustration

Each gram of Triamcinolone Acetonide (triamcinolone acetonide foam) Cream USP, 0.i% contains i mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-lx, polysorbate-80, propylene glycol and purified water.

INDICATIONS

Triamcinolone acetonide (triamcinolone acetonide foam) cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

DOSAGE AND ADMINISTRATION

Employ to affected area 2 or three times daily. Rub in gently.

Occlusive Dressing Technique

Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Gently rub a pocket-sized amount of cream into the lesion until information technology disappears. Reapply the preparation leaving a thin coating on the lesion, encompass with a pliable nonporous film, and seal the edges. If needed, boosted wet may be provided by roofing the lesion with a dampened clean cotton fiber cloth earlier the nonporous pic is applied or by briefly wetting the affected surface area with h2o immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to utilise triamcinolone ace-tonide cream nether an occlusive dressing in the evening and to remove the dressing in the morning (i.east., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional foam should be applied, without apoplexy, during the day. Reapplication is essential at each dressing alter. If an infection develops, the utilise of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

Triamcinolone Acetonide (triamcinolone acetonide cream) Cream USP, 0.1% in xv g (NDC 51672-1282-1), 30 one thousand (NDC 51672-1282-2) and fourscore g (NDC 51672-1282-eight) tubes.

Store at controlled room temperature fifteen°-30°C (59°-86°F). Protect from freezing.

Mfd. by Taro Pharmaceuticals Inc., Brampton, Ontario, Canada L6T 1C1 Dist. by: Taro Pharmaceuticals U.S.A., Inc., Hawthorne, NY 10532. Revised: May, 2005. FDA Rev date:

QUESTION

Psoriasis causes the top layer of pare cells to get inflamed and grow besides quickly and flake off. See Answer

Side Furnishings & Drug Interactions

SIDE EFFECTS

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the utilize of occlusive dressings. These reactions are listed in an approximate decreasing gild of occurrence:

Burning
Itching
Irritation
Dryness
Folliculitis

Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis

Maceration of the peel
Secondary infection
Pare cloudburst Striae
Miliaria

DRUG INTERACTIONS

No information provided.

WARNINGS

No information provided.

PRECAUTIONS

General

Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary adrenal (HPA) axis suppression, manifestations of Cushing'southward syndrome, hyperglycemia, and glucosuria in some patients.

Atmospheric condition which augment systemic absorption include the application of the more potent steroids, use over big surface areas, prolonged use, and the improver of occlusive dressings.

Therefore, patients receiving a large dose of a stiff topical steroid practical to a large area or nether an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression past using the urinary free cortisol and ACTH stimulation tests, and for impairment of thermal homeostasis. If HPA axis suppression or tiptop of the body temperature occurs, an attempt should be made to withdraw the drug, to reduce the frequency of application, substitute a less potent steroid, or utilise a sequential arroyo when utilizing the occlusive technique.

Recovery of HPA axis function and thermal homeostasis are generally prompt and consummate upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Occasionally, a patient may develop a sensitivity reaction to a particular occlusive dressing cloth or adhesive and a substitute material may be necessary.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more than susceptible to systemic toxicity (see PRECAUTIONS - Pediatric Apply section).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does non occur promptly, the corticosteroid should be discontinued until the infection has been fairly controlled.

These preparations are not for ophthalmic use.

Laboratory Tests

A urinary free cortisol test and ACTH stimulation examination may be helpful in evaluating HPA centrality suppression.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

Long-term animal studies take not been performed to evaluate the carcinogenic potential or the event on fertility of topical corticosteroids.

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy.

Teratogenic Effects, Pregnancy Category C

Corticosteroids are more often than not teratogenic in laboratory animals when administered systemical-ly at relatively low dosage levels. The more strong corticosteroids have been shown to exist ter-atogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential adventure to the fetus. Drugs of this grade should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers

It is non known whether topical administration of corticosteroids could result in sufficient systemic assimilation to produce detectable quantities in chest milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should exist exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use

Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger peel surface expanse to body weight ratio.

Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing'due south syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, depression plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Assistants of topical corticosteroids to pediatric patients should exist limited to the to the lowest degree amount uniform with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.

Overdosage & Contraindications

OVERDOSE

Topically practical corticosteroids can be captivated in sufficient amounts to produce systemic effects (encounter PRECAUTIONS, Full general section).

CONTRAINDICATIONS

Triamcinolone acetonide (triamcinolone acetonide cream) foam is contraindicated in those patients with a history of hypersensitivity to whatever of the components in the preparation.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive deportment.

The machinery of anti-inflammatory activity of topical corticosteroids is unclear. Diverse laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to propose that a recognizable correlation exists between vasoconstrictor authorization and therapeutic efficacy in homo.

Pharmacokinetics

The extent of percutaneous assimilation of topical corticosteroids is determined past many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be captivated from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increment the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION department).

Once absorbed through the peel, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are so excreted past the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

PATIENT Data

Patients using topical corticosteroids should receive the post-obit information and instructions:

This medication is to be used every bit directed past the physician. It is for external use just. Avoid contact with the eyes.
Patients should be advised not to utilise this medication for whatever disorder other than for which it was prescribed.
The treated skin area should not be bandaged or otherwise covered or wrapped as to exist occlusive unless directed by the md.
Patients should written report whatsoever signs of local adverse reactions especially nether occlusive dressings.
Parents of pediatric patients should be advised not to use tight-plumbing equipment diapers or plastic pants on a child being treated in the diaper surface area, every bit these garments may found occlusive dressings.

From

FDA Logo

Study Issues to the Food and Drug Administration

Y'all are encouraged to report negative side furnishings of prescription drugs to the FDA. Visit the FDA MedWatch website or call ane-800-FDA-1088.